Key Dates

Related Announcements

• September 01, 2023  - HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3 - Clinical Trial Optional). See NOFO RFA-NS-24-023.

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this notice is to inform potential applicants that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is participating in  RFA-NS-24-023 , “ HEAL INITIATIVE: Development and validation of remote or patient wearable device derived objective biosignatures or functional assessments to monitor pain for use as endpoints in clinical trials (UG3/UH3 - Clinical Trial Optional)” , effective immediately.

The following sections of RFA-NS-24-023 have been modified to reflect NIBIB's participation in this NOFO.

Part 1. Overview Information

Components of Participating Organizations

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Assistance Listing Number(s)

93.853, 93.865, 93.273, 93.866, 93.313, 93.213, 93.393, 93.395, 93.394, 93.286

Section VII. Agency Contacts

Scientific/Research Contact(s)

Tiffany Lash, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-4778 
Email:  [email protected] 

Inquiries

Please direct all inquiries to:

Tiffany Lash, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-4778 
Email:  [email protected]